Video

Dr. Lonial on Unanswered Questions With T-Cell Engagers in Myeloma

Sagar Lonial MD, FACP, discusses unanswered questions with T-cell engagers in myeloma.

Sagar Lonial MD, FACP, chief medical officer of Winship Cancer Institute, as well as the Anne and Bernard Gray Family Chair in Cancer and professor and chair, Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses unanswered questions with T-cell engagers in myeloma.

One need that must be addressed is the need for longer follow-up in order to identify the duration of response (DOR) associated with T-cell engagers, Lonial, says. Investigators had hoped the CAR T-cell therapies would yield longer responses in this patient population then what has previously been observed. This would have been desirable by patients, due to the fact that a single infusion is required before completing treatment, which offers a convenient option, Lonial explains.

As T-cell engagers are given continuously over a certain amount of time, it's possible a longer DOR will be observed, though it is not currently known if that will be the case, Lonial concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity